COMMUNIQUÉS West-GlobeNewswire

Essilor : Nombre total de droits de vote et d'actions composant le capital social au 28 février 2018
05/03/2018
Nombre total de droits de vote et d'actions composant le capital social au 28 février 2018 (Article L.233-8 II du Code de Commerce et les articles 221-1 et 223-16 du Règlement Général de l'AMF) Charenton-le-Pont, France [...]
VALNEVA : Déclaration d'actions et de droits de vote - février 2018
05/03/2018
VALNEVA Déclaration d'actions et de droits de vote - FEVRIER 2018 Dénomination sociale : VALNEVA Adresse du siège social : World Trade Center Lyon - Tour Oxygène, 10-12 Boulevard Marius Vivier Merle, 69003 Lyon Marché [...]
Shire plc : Director/PDMR Shareholding
05/03/2018
Director/PDMR Shareholding March 5, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transactions by person discharging managerial responsibilities 1. Details of the person discharging managerial [...]
Asthma Adherence Management Findings Utilizing Adherium’s Smartinhaler™ Technology Presented at AAAAI/WAO
05/03/2018
SAN MATEO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR), announced the presentation of new study results utilizing the Smartinhaler TM technology at the Joint Congress of the American Academy of Allergy [...]
Ossur Hf : Össur hf. initiates a new share buyback program
05/03/2018
Announcement from Össur hf. No. 16/2018 Reykjavík, 5 March 2018 Össur hf. has decided to initiate a new share buyback program (the "Program") tomorrow, 6 March 2018, which will replace the share buyback program that was [...]
Ossur Hf : Share buyback program completed
05/03/2018
Announcement from Össur hf. No. 15/2018 Reykjavík, 5 March 2018 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program was to [...]
Shire plc : U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
05/03/2018
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation NDA acceptance of prucalopride reinforces Shire's long-standing heritage in gastrointestinal (GI) conditions and deep [...]
The Alliance for Regenerative Medicine Releases 2017 Annual Data Report, Highlighting Sector Trends and Metrics
05/03/2018
WASHINGTON, D.C., March 05, 2018 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM) today announced the release of its 2017 Annual Data Report, offering an in-depth look at trends and metrics for the cell [...]
Tetra Bio-Pharma Announces Closing of Bought Deal Financing
05/03/2018
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OTTAWA, March 05, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“ Tetra ” or the “ Corporation ”) (TSX-V: TBP ) (OTCQB: [...]
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
05/03/2018
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation NDA acceptance of prucalopride reinforces Shire's long-standing heritage in gastrointestinal (GI) conditions and deep [...]
Celsion Announces Ovarian Cancer Expert Presentation at Oppenheimer & Co. Investor Event
05/03/2018
LAWRENCEVILLE, N.J., March 05, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) today announced that Premal H. Thaker, M.D., M.S., Associate Professor of Obstetrics and Gynecology at the Siteman Cancer Center [...]
Transactions under Novozymes’ stock buyback program
05/03/2018
Please read the full announcement in the attached PDF 2018_06_Stock_Buybackprogram_EN
Sharecare Introduces New Unified, Cloud-Based Platform for Medical Record Retrieval Services
05/03/2018
ATLANTA and LAS VEGAS, March 05, 2018 (GLOBE NEWSWIRE) -- Sharecare , the digital health company that helps people manage all their health in one place, today announced at HIMSS18 that its affiliate Sharecare Health [...]
ViewPoint Therapeutics Raises $35 Million in Series B Financing
05/03/2018
-- Proceeds will advance lead product candidate through clinical proof-of-concept studies in cataracts and presbyopia -- -- Series B led by The Rise Fund, a global impact fund -- SAN FRANCISCO, March 05, 2018 (GLOBE [...]
Share buy-back week 9/2018
05/03/2018
Announcement 5 March 2018 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 3/2018 Coloplast has initiated the first part of the share buy-back programme totalling up [...]
Allakos Highlights Data Demonstrating Potential of AK002 to Rapidly Deplete Eosinophils at 2018 AAAAI/WAO Joint Congress
05/03/2018
-- Phase 1 data demonstrate AK002 rapidly depletes blood eosinophils after a single dose -- -- AK002 may provide an important new option in treating chronic allergic and inflammatory diseases such as eosinophilic [...]
Andrew Read to Join Board of Directors of International Endeavors Corporation
05/03/2018
TEMECULA, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--- International Endeavors Corporation, a Medical Marijuana IP Holdings Company today announced that Andrew Read has agreed to join the company’s [...]
Aquinox Pharmaceuticals to Announce Year End 2017 Financial Results
05/03/2018
VANCOUVER, British Columbia, March 05, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ: AQXP ), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to [...]
Oregon Proves To Be Burgeoning Success for Advantis Corp.
05/03/2018
SEATTLE, WA, March 05, 2018 (GLOBE NEWSWIRE) -- ADVANTIS CORPORATION (OTC PINK: ADVT) reported that their partners in Oregon just logged an order for almost fifteen times their original order, and may soon double that [...]

Pages